Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

Overview of attention for article published in Cost Effectiveness and Resource Allocation, August 2021

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 X post from an account with 2,170 followers.

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China https://t.co/Hsf2aTLTPq

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.